Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

This study has been terminated.
(Corporate decision to reformulate the investigational product.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Tekmira Pharmaceuticals Corporation
ClinicalTrials.gov Identifier:
NCT01518881
First received: November 8, 2011
Last updated: January 8, 2014
Last verified: January 2014
  Purpose

This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study with additional multiple-ascending dose cohorts in healthy male and female volunteers.


Condition Intervention Phase
Ebola Virus Infection
Drug: TKM-100201
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability and Pharmacokinetics of TKM-100201 in Healthy Human Volunteers

Resource links provided by NLM:


Further study details as provided by Tekmira Pharmaceuticals Corporation:

Primary Outcome Measures:
  • Safety and Tolerability of Treatment with TKM-100201 [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

    Subjects will be monitored for treatment-emergent and dose-limiting toxicity (DLT). If there are any adverse events (changes from baseline in laboratory parameters, vitals and/or infusion reactions) during these monitoring periods, the Independent Safety Committee, will discuss the dosing of the remaining subjects.

    Before proceeding to the next dose cohort, the Independent Safety Committee will evaluate whether dose escalation will be permitted based on demonstration of adequate safety and tolerability.



Secondary Outcome Measures:
  • Pharmacokinetics - Cmax, Tmax and AUC will be calculated [ Time Frame: 29 days post infusion ] [ Designated as safety issue: No ]
    Time-points: Before infusion, mid-point of infusion, end of infusion and at 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 16, 24, 48 hours after infusion and day 7, day 10, day 15, day 22 and day 29.


Enrollment: 24
Study Start Date: January 2012
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TKM-100201 Drug: TKM-100201
IV Infusion
Other Name: TKM-Ebola
Placebo Comparator: Placebo Drug: Placebo
IV infusion
Other Name: Normal Saline

Detailed Description:

A maximum of 56 healthy adult (male and female) subjects will participate in this study, in two stages. In Stage 1, the Single-Ascending Dose (SAD) phase of the study will have up to six cohorts with 4 subjects (3 receiving TKM-100201 and 1 receiving saline placebo) in each cohort. Additional cohorts may be enrolled if a maximum tolerated dose (MTD) is not established after the initial six cohorts. In Stage 2, the Multiple-Ascending Dose (MAD) portion of the study will have up to three cohorts with four subjects (3 receiving TKM-100201 and 1 receiving saline placebo) in each cohort. Additional cohorts may be enrolled if a maximum tolerated dose (MTD) is not established after the initial three cohorts.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed of the nature of the study and have agreed to and are able to read, review and sign the informed consent document at screening. The informed consent document will be written in English, therefore the volunteer must have the ability to read and communicate in English.
  2. Able to comply with all protocol-specified visit schedules and requirements.
  3. Completed the screening process within 14 days prior to dosing.
  4. Healthy male and female volunteers 18 to 50 years of age, inclusive, at the time of dosing.
  5. Body mass index (BMI) between 22 kg/m2 to 35 kg/m2, inclusive, and weigh at least 110 lbs.
  6. Judged by an Investigator to be in good health as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead ECG, clinical laboratory assessments, and by general observations. Any abnormalities or deviations outside the normal ranges for any of clinical testing (laboratory tests, ECG, vital signs) can be repeated at the discretion of the Investigator(s) and judged to be not clinically significant for study participation.
  7. Adequate hepatic, renal, hematologic and clotting function as defined by total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum creatinine, D-dimer and International normalized ratio (INR) within normal range as determined by the Investigator(s) and Sponsor Medical Monitor.
  8. Female volunteers must be one of the following:

    • naturally postmenopausal (no menses) for > 2 years and has a documented FSH level >40 mIU/mL; or
    • have a documented history of ovarian failure; or
    • surgically postmenopausal (bilateral oophorectomy or hysterectomy). Female volunteers that are surgically postmenopausal must provide documentation of the bilateral oophorectomy or hysterectomy prior to Day 1 dosing to be eligible for participation in the study; or
    • Women of childbearing potential (FSH ≤40 mIU/mL) must have negative serum hCG at screening, a negative urine pregnancy test prior to the first study treatment, and must agree to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be non-heterosexually active, or have a vasectomized partner) from screening throughout the duration of study treatment and for 1 month after the last administration of investigational product.
  9. Male volunteers who are sexually active must be willing to use effective barrier contraception (e.g., condom with spermicide) during heterosexual intercourse from screening throughout the duration of study treatment and for 1 month after the last dose of investigational product.

Exclusion Criteria:

  1. Evidence or history of clinically significant hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease at screening or medication for comorbidity which, in dialogue between the Investigator and Medical Monitor would preclude subject participation in the clinical trial.
  2. Reports an uncontrolled psychiatric disorder or neurologic disease or seizure disorder not controlled by medication.
  3. Subject has a history of existing clinically significant cardiovascular disease (for example, uncontrolled hypertension, unstable angina, congestive heart failure or serious cardiac arrhythmias). In addition New York Heart Association Functional Classification Class II or greater will be excluded (see Appendix).
  4. Reports history of coronary heart disease (CHD), CHD-equivalent disease or CHD risk >20% as designated by the National Cholesterol Education Program Adult Treatment Panel III.
  5. Current diagnosis or known history of liver disease (e.g. acute or chronic hepatitis or liver cirrhosis).
  6. Presence of any clinically significant results from laboratory tests, vital signs assessments and ECGs as judged by the Investigator(s).
  7. Reports receiving any antiviral drugs, investigational drugs, biologics, or devices within 28 days prior to study treatment or planned use during the course of the study.
  8. Reports receiving naturopathic medications, herbal supplements, or lipid lowering therapies within 28 days prior to study treatment of planned use during the course of the study.
  9. Recent treatment with alternative therapies which, in the view of the Investigator(s) or the Medical Monitor, could potentially confound clinical and laboratory assessments.
  10. Demonstrates a marked baseline prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval >450 ms)
  11. Reports concomitant use of any medication that prolongs the QT/QTc interval.
  12. Reports a history of additional risk factors for torsades de pointes (e.g. heart failure, hypokalemia, family history of Long QT Syndrome).
  13. When confirmed upon additional testing, demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
  14. Reports infections requiring antibiotic therapy within 30 days of screening (as determined by the Investigator[s]).
  15. Reports a history of Ebola virus exposure.
  16. Reports an occupational health risk of exposure to Ebola virus known to be higher than that of the general population.
  17. Reports a known or suspected hypersensitivity or previous severe reactions to any of the constituents of the investigational product including oligonucleotide- or lipid-based products, liposomal drug products, and phospholipid-based products (parenteral nutrition, Intralipid).
  18. Reports a history of clinically significant allergies including food or drug allergies.
  19. Demonstrates a positive drug or alcohol screen.
  20. Reports a history of drug or alcohol addiction or abuse within the past 1 year.
  21. Subject is unwilling to limit alcohol consumption during the study (males: 2 drinks/day [30 g], <12 drinks/week [120 g] and females: 2 drinks/day [20 g], <12drinks/week [120 g]).
  22. Reports donating blood within 28 days prior to dosing. All volunteers will be advised not to donate blood for four weeks after completing the study.
  23. ports donating plasma (eg, plasmapheresis) within 14 days prior to dosing. All volunteers will be advised not to donate plasma for four weeks after completing the study.
  24. Demonstrates, in the opinion of study staff, veins unsuitable for repeated venipuncture or IV infusion (eg, veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
  25. Reports being capable of becoming pregnant, breastfeeding, or lactating.
  26. Demonstrates a positive pregnancy screen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01518881

Locations
United States, North Dakota
Cetero Research
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Tekmira Pharmaceuticals Corporation
Investigators
Principal Investigator: Gregory M Haugen, M.D. Cetero Research, San Antonio
  More Information

No publications provided

Responsible Party: Tekmira Pharmaceuticals Corporation
ClinicalTrials.gov Identifier: NCT01518881     History of Changes
Other Study ID Numbers: TKM-EBOV-001
Study First Received: November 8, 2011
Last Updated: January 8, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Virus Diseases
Hemorrhagic Fever, Ebola
Hemorrhagic Fevers, Viral
RNA Virus Infections
Filoviridae Infections
Mononegavirales Infections

ClinicalTrials.gov processed this record on August 21, 2014